Viltolarsen (Viltepso)

Viltepso is FDA‑approved for DMD patients with a confirmed DMD gene mutation amenable to exon 53 skipping, but Evicore does not recommend coverage because clinical benefit has not been established and clinical efficacy data are lacking. Documentation of a confirmed exon‑53‑amenable DMD mutation and meeting all applicable coverage/safety criteria is required, and continued approval is contingent on confirmatory trials.

"Viltepso is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping."

Sign up to see full coverage criteria, indications, and limitations.